Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Ross Baker, Chih-Cheng Chen, Tsai-Yun Chen, Stanley Cheung, Hui-Hua Hsiao, Jae Hoon Lee, Ji Yun Lee, Sung-Eun Lee, Won Sik Lee, Lucia Masarova, Peter Tan, Shuhying Tan, Pankit Vachhani, Anne Marie Watson, Shang-Ju Wu, Jana Baskar, Joanna Leadbetter, Wolfgang Jarolimek

Blood (2025) 146 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2025-2027

Published: 2025

Journal Articles

FLT3L-based conjugate targets chemoresistant leukemia stem cells via cell cycle re-entry in Acute Myeloid Leukemia

Dengyang Zhang, Yao Guo, Zhiyong Peng, Yan Xiao, Zhiguang Chang, Liuting Yu, Yuming Zhao, Qi Zhang, Lingling Ma, Shuping Li, Chi Kong Li, Kam Tong Leung, Zhizhuang Zhao, Chun Chen, Yun Chen

Blood (2025) 146 (Supplement 1): 319.

https://doi.org/10.1182/blood-2025-319

Published: 2025

Journal Articles

PTPN11 copy number gain drives leukemogenesis via mutant SHP2 in juvenile myelomonocytic leukemia

Zhiguang Chang, Zhiyong Peng, Lingling Ma, Yan Xiao, Yao Guo, Dengyang Zhang, Yuming Zhao, Liuting Yu, Junbin Huang, Hongman Xue, Chi Kong Li, Chun Chen, Zhizhuang Zhao, Yun Chen

Blood (2025) 146 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2025-3234

Published: 2025

Journal Articles

Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study

Li-Yang Shiau, Chien-Yun Chen, Hao-Yuan Wang, Hung-Cheng Tsai, Sunny Ssu-Yu Chen, Tina Ting-An Lin, Yi-Lin Chiang, Po-Shen Ko

Blood (2025) 146 (Supplement 1): 3959.

https://doi.org/10.1182/blood-2025-3959

Published: 2025

Journal Articles

Genetic evolution in CML patients from diagnosis to TKI failure: An analysis of 121 paired diagnosis and treatment failure samples

Ying-Jung Huang, Ming-Chung Kuo, Tung-Liang Lin, Ming-Chun Ma, Chieh-Lin Jerry Teng, Young-Sen Yang, Tsai-Yun Chen, Chiu-Chen Chen, Cheng-Shyong Chang, Hung Chang, Ting-Yu Huang, Tung-Huei Lin, Yen-Min Huang, Su-Peng Yeh, Ming-Chung Wang, Lee-Yung Shih

Blood (2025) 146 (Supplement 1): 5555.

https://doi.org/10.1182/blood-2025-5555

Published: 2025

Journal Articles

Long-acting GM-CSF-based drug conjugate effectively targets leukemia stem cells in Acute Myeloid Leukemia with limited toxicity

Yan Xiao, Yao Guo, Dengyang Zhang, Zhiyong Peng, Yuming Zhao, Zhiguang Chang, Liuting Yu, Lingling Ma, Chi Kong Li, Zhizhuang Zhao, Chun Chen, Yun Chen

Blood (2025) 146 (Supplement 1): 752.

https://doi.org/10.1182/blood-2025-752

Published: 2025

Journal Articles

PI3Kδ inhibition enhances trametinib efficacy by suppressing feedback-activated PI3K/AKT signaling in PTPN11-mutant JMML

Yuming Zhao, Yao Guo, Zhiyong Peng, Tianqi Liang, Zhiguang Chang, Yan Xiao, Dengyang Zhang, Liuting Yu, Lingling Ma, Chi Kong Li, Zhizhuang Zhao, Chun Chen, Yun Chen

Blood (2025) 146 (Supplement 1): 5010.

https://doi.org/10.1182/blood-2025-5010

Published: 2025

Journal Articles

Immunophenotypic and cytokine profiling reveal robust immunomodulation after dasatinib treatment and identify a subgroup with rapid and deep molecular response in CML patients: A multi-center prospective study

Shih-Feng Cho, Tsai-Yun Chen, Ying-Chung Hong, Ming-Chung Wang, Yu-Fen Tsai, Tsung-Jang Yeh, Hung-Pin Tu, Sin-Hua Moi, Hui-Ching Wang, Jeng-Shiun Du, Yuh-Ching Gau, Ching-I Yang, Ching-Ping Lee, Wen-Hsin Chang, Chin-Mu Hsu, Hui-Hua Hsiao, YI-Chang Liu

Blood (2025) 146 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2025-1975

Published: 2025

Journal Articles

Identification of factors associated with a high success rate of treatment-free remission in chronic myeloid leukemia: A multicenter study in Taiwan

Ning-Chun Chen, Ming-Chung Kuo, Tung-Huei Lin, Ming-Chun Ma, Ching-Yuan Kuo, Hung Chang, Hsuan-Jen Shih, Tung-Liang Lin, Hsiao-Wen Kao, Chang-Liang Lai, Tsai-Yun Chen, Chih-Cheng Chen, Ming-Chung Wang, Lee-Yung Shih

Blood (2025) 146 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2025-3781

Published: 2025

Journal Articles

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 843.

https://doi.org/10.1182/blood-2025-843

Published: 2025

Journal Articles

Targeting SP1 condensates suppresses HNRNPUL1 via super-enhancers to attenuate Acute Myeloid Leukemia progression

Yuchen Wen, Chun Chen, Chi Kong Li, Yun Chen

Blood (2025) 146 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2025-3267

Published: 2025

Journal Articles

FBXO7 通过靶向 TMED10 进行泛素介导的降解和激活 wnt 信号传导来促进 T-ALL 的化疗耐药性

zefan du, ouyang cheng, Chi Kong Li, Yun Chen, Chun Chen

Blood (2025) 146 (Supplement 1): 3263.

https://doi.org/10.1182/blood-2025-3263

Published: 2025

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Blood (2024) 144 (Supplement 1): 4569.3.

https://doi.org/10.1182/blood-2024-200881

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Seok-Goo Cho, Tae Min Kim, Michal Taszner, Tsai-Yun Chen, Aafia Choudhry, Melanie Ufkin, Amulya Uppala, Ayesha Sabir, Hesham Mohamed, Srikanth Ambati, Emmanuel Bachy

Blood (2024) 144 (Supplement 1): 6302.

https://doi.org/10.1182/blood-2024-200770

Published: 2024

Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2024-200914

Published: 2024

Journal Articles

The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy

Wenqing Wang, Yan-lai Tang, Zhen Li, Hao Jiang, Chi-Kong Li, Chun Chen, Yun Chen, Hongman Xue

Blood (2023) 142 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2023-187653

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

FLT3L-based conjugate targets chemoresistant leukemia stem cells via cell cycle re-entry in Acute Myeloid Leukemia

PTPN11 copy number gain drives leukemogenesis via mutant SHP2 in juvenile myelomonocytic leukemia

Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study

Genetic evolution in CML patients from diagnosis to TKI failure: An analysis of 121 paired diagnosis and treatment failure samples

Long-acting GM-CSF-based drug conjugate effectively targets leukemia stem cells in Acute Myeloid Leukemia with limited toxicity

PI3Kδ inhibition enhances trametinib efficacy by suppressing feedback-activated PI3K/AKT signaling in PTPN11-mutant JMML

Immunophenotypic and cytokine profiling reveal robust immunomodulation after dasatinib treatment and identify a subgroup with rapid and deep molecular response in CML patients: A multi-center prospective study

Identification of factors associated with a high success rate of treatment-free remission in chronic myeloid leukemia: A multicenter study in Taiwan

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Targeting SP1 condensates suppresses HNRNPUL1 via super-enhancers to attenuate Acute Myeloid Leukemia progression

FBXO7 通过靶向 TMED10 进行泛素介导的降解和激活 wnt 信号传导来促进 T-ALL 的化疗耐药性

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only